Accueil/Actions/DERM

DERM

USD

Journey Medical Corporation Common Stock

$9.000+0.590 (7.015%)

Prix en Temps Réel

Healthcare

Drug Manufacturers - Specialty & Generic

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$8.410

Haut

$9.010

Bas

$8.260

Volume

0.22M

Fondamentaux de l'Entreprise

Capitalisation Boursière

236.8M

Industrie

Drug Manufacturers - Specialty & Generic

Pays

United States

Statistiques de Trading

Volume Moyen

0.16M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $3.535Actuel $9.000Haut $9.01

Actualités Connexes

24 oct. 2025 · 12:30

GlobeNewswire

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

8 oct. 2025 · 12:30

GlobeNewswire

Journey Medical Corporation to Participate in October 2025 Investor Conferences

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing